<!-- Document ID: original -->
<!-- Title: 1. DEFINITIONS AND INTERPRETATION -->
<!-- Chunk: 27/93 -->
<!-- Length: 11150 characters -->
1. any trade credit or advance payments extended by any Group Company to its customers on normal commercial terms and in the ordinary course of its trading activities and advance payments made in relation to capital expenditure in the ordinary course of business;
2. Financial Indebtedness which is referred to in the definition of, or otherwise constitutes, "Permitted Financial Indebtedness" (except under paragraph (d) of that definition);
3. a loan made to a Joint Venture to the extent permitted under clause 26.10 (Joint Ventures);
4. a loan made by an Obligor to another Obligor or made by a Non-Obligor to another Group Company (other than the Parent);
5. any loan made by an Obligor to a Non-Obligor so long as the aggregate amount of the Financial Indebtedness under any such loans (when added to the aggregate amounts guaranteed pursuant to paragraph (f) of the definition of "Permitted Guarantee" does not exceed £160,000 (or its equivalent in other currencies) at any time;
6. a loan made by a Group Company to an employee or director of any Group Company if the amount of that loan when aggregated with the amount of all loans to employees and directors by Group Companies does not exceed £80,000 (or its equivalent in other currencies) at any time;
7. any loan made to an employee benefit trust or similar for the purpose of the operation of an employee share scheme or similar subject to the maximum total amount of all such loans not exceeding £150,000 (or its equivalent in other currencies) at any time;
8. any deferred consideration on Permitted Disposals and/or any loans or other extensions of credit made by a member of the Group that are or may become due or remain outstanding as a result of or following such disposal provided that the aggregate outstanding amount of such credit or consideration does not at any time exceed £200,000;
9. loans or extensions of credit resulting from any guarantee, netting or set-off under arrangements described under paragraph (e) of the definition of "Permitted Guarantee";

(j) any loan made by a member of the Group for the purposes of enabling the Parent or an Obligor to meet its payment obligations under the Senior Finance Documents or to make a Permitted Payment;

(k) loans to the extent constituted by an investment in Cash Equivalent Investments or positive cash balances on bank accounts; and

(l) any loan not permitted by the preceding paragraphs (other than a loan made by a Group Company to another Group Company) so long as the aggregate amount of the Financial Indebtedness under any such loans does not exceed £200,000 (or its equivalent in other currencies) at any time,

so long as the provision of such loan or other credit is not made in breach of the Intercreditor Agreement and, in the case of paragraphs (d), (e) and (f) above:

- (i) the creditor of such Financial Indebtedness shall (if it is an Obligor) grant security over its rights in respect of such Financial Indebtedness in favour of the Secured Parties on terms acceptable to the Facility Agent (acting on the instructions of the Majority Lenders); and
- (ii) to the extent required by the Intercreditor Agreement the creditor and the debtor of such Financial Indebtedness are or become party to the Intercreditor Agreement as an Intra-Group Lender and a Debtor (as defined, in each case, in the Intercreditor Agreement) respectively;

"Permitted Payment" means:

1. (a) the payment of a dividend, payment of interest, repayment of principal or loan or fee by Parent to any Holding Company or shareholder of Parent:
2. - (i) to meet:
- - (A) administrative costs, directors' fees and other out of pocket expenses (up to £20,000 in each Financial Year plus VAT); and
- (B) an arrangement fee payable to the Investors in the amount of £1,196,597 on or before the Closing Date;

(ii) any arrangement fee (funded in full by a New Shareholder Injection) relating to any New Shareholder Injection in connection with the funding of a Permitted Acquisition up to the higher of:
- - (A) 3% of the enterprise value of any target company or business which is the subject of such an acquisition; and
- (B) 7% of such New Shareholder Injection; and

(iii) an arrangement fee (funded in full by a New Shareholder Injection) in respect of any guarantee issued by the Investors or its Sponsor Affiliates in respect of the obligations of any Group Company up to a maximum of 3% of the guaranteed liabilities arising under such guarantee,

in each case, as increased by up any increase in the UK's retail price index in each Financial Year and irrespective of whether any Event of Default is continuing at such time;

(b) a payment by way of capitalisation of interest and/or any related PIK note in accordance with the Loan Notes, Management Loan Notes or any other Investor Instrument;

UK - 205885966.10 34

(c) payment of fees and costs for the Acquisition as set out in the Funds Flow Statement and for any other Permitted Acquisition as set out in the related funds flow statement for that Permitted Acquisition;

(d) the payment of fees, costs, and expenses in respect of New Shareholder Injections by way of deduction from such New Shareholder Injection (but so that only the net amount received by the Group shall be treated as the amount of the New Shareholder Injection for the purposes of this Agreement);

(e) subject to paragraph (h) below, the payment by the Parent of scheduled cash-pay interest (quarterly and in arrears, save in respect of the first payment due on 30 June 2016 which shall accrue from the Closing Date) on Investor Instruments or Management Loan Notes (except for those used to remedy a breach of a financial covenant pursuant to clause 25.4 (Equity Cure)) (a "Proposed Payment"), provided that:

- (i) the Parent has been in compliance with its obligations under clause 25 (Financial Covenants) for the Relevant Period prior to making the relevant payment (calculated as if the Proposed Payment and any Unpaid Interest, as defined below had been paid at the end of that Relevant Period);
- (ii) EBITDA of the Group for the Relevant Period ending on or around the date on which such scheduled interest payment is due is not lower than the amount set out in column 2 below opposite that Relevant Period (the "EBITDA Test").

| Column 1                                   | Column 2   |
| ------------------------------------------ | ---------- |
| Relevant Period                            | £          |
| Relevant Period expiring 30 June 2016      | £3,739,422 |
| Relevant Period expiring 30 September 2016 | £3,773,692 |
| Relevant Period expiring 31 December 2016  | £4,493,562 |
| Relevant Period expiring 31 March 2017     | £4,800,299 |
| Relevant Period expiring 30 June 2017      | £5,016,634 |
| Relevant Period expiring 30 September 2017 | £5,204,829 |
| Relevant Period expiring 31 December 2017  | £5,318,657 |
| Relevant Period expiring 31 March 2018     | £5,328,708 |
| Relevant Period expiring 30 June 2018      | £5,493,834 |
| Relevant Period expiring 30 September 2018 | £5,639,064 |
| Relevant Period expiring 31 December 2018  | £5,790,271 |
| Relevant Period expiring 31 March 2019     | £5,970,787 |
| Relevant Period expiring 30 June 2019      | £6,115,229 |
| Relevant Period expiring 30 September 2019 | £6,239,082 |

# Relevant Period

| Relevant Period                                                                     | £          |
| ----------------------------------------------------------------------------------- | ---------- |
| Relevant Period expiring 31 December 2019                                           | £6,368,286 |
| Relevant Period expiring 31 March 2020                                              | £6,528,966 |
| Relevant Period expiring 30 June 2020                                               | £6,696,616 |
| Relevant Period expiring 30 September 2020                                          | £6,842,483 |
| Relevant Period expiring 31 December 2020                                           | £6,993,777 |
| Relevant Period expiring 31 March 2021 and each Relevant Period expiring thereafter | £7,178,367 |

(iii) the Parent forecasts that it will comply with its obligations under clause 25 (Financial Covenants) for the 12 month period following the relevant payment (calculated after taking account of the Proposed Payment and any Unpaid Interest, as defined below);

(iv) no Default is continuing or would occur as a result of the Proposed Payment;

(v) only one payment may be made under this paragraph (e) in any Financial Quarter; and

(vi) the Parent has delivered the Compliance Certificate required pursuant to clause 24.2 (Provision and Contents of Compliance Certificate) for the Relevant Period that ended on or around the date on which such scheduled interest payment is due, at least 10 days prior to the date of payment confirming compliance with the requirements specified above.

(f) Any Proposed Payment or payment of Unpaid Interest (as defined below) or payment of capitalised interest on any Investor Instrument or Management Loan Note, provided that in each case it is made solely from the cash receipts of a New Shareholder Injection solely for the purposes of making (and in an amount not exceeding) as the case may be, such Proposed Payment paid pursuant to paragraph (e) above or Payment of Unpaid Interest or payment of capitalised interest in cash prior to the date payment is made, as certified by the Parent period to the date payment is made.

To the extent a Proposed Payment made in full would cause a breach of paragraph (i) to (vi) above but a partial payment would not, a partial payment may be made (the unpaid amount being the "Unpaid Interest"). Any Unpaid Interest may subsequently be paid along with any Proposed Payment, if when added to the Proposed Payment it would meet the relevant tests at paragraphs (i) to (vi) above. The Compliance Certificate delivered pursuant to this paragraph shall specify the amount of the Proposed Payment and any Unpaid Interest to be paid at the same time;

(g) Subject to paragraph (h) below any payment of principal or scheduled cash-pay interest or capitalised interest (and any related PIK notes) in respect of any Investor Instruments or Management Loan Notes and payment of any dividend to any shareholder of the Parent if:

(i) funded entirely from the Overfund Amount; or

# 11.2 Disposal, Insurance and Acquisition Proceeds and Excess Cashflow

(ii) funded entirely from Excess Cashflow not required to repay the Term Loans pursuant to clause 11.2 (Disposal, Insurance and Acquisition Proceeds and Excess Cashflow) and provided that:

- (A) no Default is continuing or would occur immediately after making such payment; and
- (B) the Leverage ratio is equal to or less than 2.5:1 (as at the most recently completed Relevant Period and pro forma for such distribution);

(h) no payment pursuant to paragraph (e), (f) or (g) above shall be permitted at any time when the Parent or any Borrower has elected to have an Interest Period of longer than 3 months for any Facility A Loan and the payment would occur during such Interest Period;